Administration of Optimum Sustained-Insulin Release PLGA Microcapsules to Spontaneous Diabetes-Prone BB/WorTky Rats

To show the possibility of sustained-release insulin formulation composed of PLGA, the optimum one was administered to BioBreeding rat, a model of spontaneous type I diabetes mellitus (IDDM). Every 2 weeks subcutaneous administration made their blood glucose level depend on the insulin release and food intake. However, all of them kept alive with little change or rather a little gain in body weight. Furthermore, some of pregnant rats with intermittent treatment bore fetuses, although additional insulin therapy seemed necessary. Therefore, the formulation could become a new tool as a provider of basal insulin for IDDM patients.

[1]  T. Haak,et al.  New developments in the treatment of type 1 diabetes mellitus. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[2]  Y. Yamaguchi,et al.  Optimum formulation for sustained-release insulin. , 2004, International journal of pharmaceutics.

[3]  S. Kawazu,et al.  Adenoviral insulin gene therapy prolongs survival of IDDM model BB rats by improving hyperlipidemia. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[4]  Y. Yamaguchi,et al.  A novel insulin formulation can keep providing steady levels of insulin for much longer periods in‐vivo , 2002, The Journal of pharmacy and pharmacology.

[5]  Y. Yamaguchi,et al.  Insulin-loaded biodegradable PLGA microcapsules: initial burst release controlled by hydrophilic additives. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Y. Yamaguchi,et al.  A novel sustained-release formulation of insulin with dramatic reduction in initial rapid release. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[7]  S. Davis,et al.  Polymeric lamellar substrate particles for intranasal vaccination. , 2001, Advanced drug delivery reviews.

[8]  J L Cleland,et al.  Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[9]  M. Morishita,et al.  Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. , 1999, Drug development and industrial pharmacy.

[10]  C. Partidos,et al.  CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles. , 1997, Journal of immunological methods.

[11]  Y. Ogawa,et al.  Sustained release of a water-soluble GP IIb/IIIa antagonist from copoly(dl-lactic/glycolic)acid microspheres , 1997 .

[12]  C. Chappel,et al.  The discovery and development of the BB rat colony: an animal model of spontaneous diabetes mellitus. , 1983, Metabolism: clinical and experimental.

[13]  A. Rossini,et al.  Spontaneous Autoimmune Diabetes Mellitus in the BB Rat , 1982, Diabetes.

[14]  L. Mandarino,et al.  Dose-response characteristics for effects of insulin on production and utilization of glucose in man. , 1981, The American journal of physiology.

[15]  W. Rutter,et al.  Isolation and characterization of a cloned rat insulin gene , 1979, Cell.

[16]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[17]  S. Gabbe.  New concepts and applications in the use of the insulin pump during pregnancy. , 2000, The Journal of maternal-fetal medicine.

[18]  Y. Ogawa.  Injectable microcapsules prepared with biodegradable poly(alpha-hydroxy) acids for prolonged release of drugs. , 1997, Journal of biomaterials science. Polymer edition.

[19]  A. Coombes,et al.  Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. , 1995, Vaccine.